A Phase 1/2 interventional study of human cord blood mononuclear cells and human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells in Autism, sponsored by Shenzhen Beike Bio-Technology Co., Ltd.. Completed at 1 site in China. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2011-10-14.
Sponsored by Shenzhen Beike Bio-Technology Co., Ltd. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Autistic Disorder with a site in China — 13 open to participants now, 15 under way, none of them phase 3. Autistic Disorder · China.
Among the 26 studies in Autistic Disorder with a site in China, this one is the 16th largest by enrollment of the 20 interventional ones that give a count, is the only one that started in 2009, is one of 2 in phase 1/2, and was the 1st registered.
1,033 studies on the registry are indexed under Autistic Disorder; 269 are open to participants now.
Browse Autistic Disorder studies →13 of the 26 studies in Autistic Disorder with a site in China are open now. Recruiting first, the newest first:
Children's Hospital of Fudan University · Sites in China
Ages 18 mo–24 mo · Healthy volunteers
Children's Hospital of Fudan University · Sites in China
Ages 3–10
Children's Hospital of Fudan University · Sites in China
Ages 2–17 · Healthy volunteers
Children's Hospital of Fudan University · Sites in China
Ages 1 mo–18 yrs
Central South University · Sites in China
Ages 3–18
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 183 Autistic Disorder studies recruiting now, 33 (18%) set no upper age limit and 143 (78%) stop at 75 or younger; 148 take children under 18; 56 take healthy volunteers.
This study: 3 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 2 · Phase 3 1
First in 2009; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 49 across 813 interventional studies indexed under Autistic Disorder.
Median enrollment 66 across the 20 interventional studies, 340 across the 6 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 26 have an industry lead sponsor. The 10 most frequent:
Shenzhen Beike Bio-Technology Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Shenzhen Beike Bio-Technology Co., Ltd. has 1 study filed under Autistic Disorder — fewer than ten, so there is no comparison to draw.
4 of the studies in Autistic Disorder with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112067Shanghai Mental Health CenterEfficacy and Safety of Combo-stim Deep Brain Stimulation for Treatment-refractory Mental Disorders | 2026-11 |
| NCT07509879Qilu Hospital of Shandong UniversityResearch on the Molecular Mechanism of Cognitive Differences Between Williams Syndrome and Autism Spectrum Disorder | 2026-12-01 |
| NCT05901558Children's Hospital of Fudan UniversityStrategies for Toddler ASD With Remote-therapy (STAR) Model for ASD | 2026-12-30 |
| NCT07435103The Children's Hospital of Zhejiang University School of MedicineXenon Therapy for Children With Autism Spectrum Disorder | 2027-03-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 26 studies in Autistic Disorder with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Autism is one of those disorders in Autism spectrum disorders (ASD), which characterized by social interaction abnormalities, impaired verbal and non-verbal communication, and repetitive, obsessive behavior, while the therapeutic effect of current treatments remains limited progress .Neural hypoperfusion and immune deregulation are the two key pathologies associated with Autism. Human umbilical cord mesenchymal stem cells (hUC-MSCs) and human cord blood mononuclear cells (hCB-MNCs) have been shown to have the ability to modulate the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic strategy. In this study, the safety and efficacy of hUC-MSCs and hCB-MNCs transplantation will be evaluated in patients with Autism.
To investigate the safety and efficacy of human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells transplantation in patients of Autism.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be given rehabilitation therapy plus human cord blood mononuclear cells transplantation with a 6 months follow-up.
Biological: human cord blood mononuclear cells
Participants will be given rehabilitation therapy plus combination of hCB-MNCs together with hUC-MSCs transplantation with a 6 months follow-up.
Biological: human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells
Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
Also known as: Group 1
Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
Also known as: Group 2
Childhood Autism Rating Scale,CARS
Time frame: 6 months after treatment
Clinical Global Impression Scale,CGI
Time frame: 6 months after treatment
Aberrant Behavior Checklist,ABC
Time frame: 6 months after treatment
Adverse Event and Serious Adverse Event
Time frame: 6 months after treatment
The record gives a start of Mar 2009, a primary completion of Jun 2010 and a completion of May 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenzhen Beike Bio-Technology Co., Ltd.